quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:45:00·72d
PRRelease
Akari Therapeutics plc logo

Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing the Company's Expanded ADC Pipeline

AKTX· Akari Therapeutics plc
Health Care
Original source

Companies

  • AKTX
    Akari Therapeutics plc
    Health Care

Recent analyst ratings

  • Apr 8UpdateMaxim Group-
  • Jan 5UpdateLadenburg Thalmann$1.00
  • Jul 18UpdateMaxim Group$5.00

Related

  • PR3d
    Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
  • PR4d
    Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing
  • SEC8d
    SEC Form EFFECT filed by Akari Therapeutics plc
  • SEC13d
    SEC Form POS AM filed by Akari Therapeutics plc
  • PR15d
    Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC
  • ANALYST16d
    Akari Therapeutics downgraded by Maxim Group
  • PR18d
    Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
  • SEC24d
    Amendment: SEC Form F-6/A filed by Akari Therapeutics plc
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022